Does Humana Cover Testosterone Cypionate?

Humana Formulary Placement for Testosterone Cypionate

Generic testosterone cypionate sits on Tier 2 or Tier 3 of most Humana commercial formularies, which translates to a copay of $10 to $45 depending on the specific plan design, pharmacy network status, and whether the member fills at a preferred pharmacy. Branded Depo-Testosterone, when stocked, usually lands on a higher non-preferred tier.

Humana updates its formulary lists quarterly. Members can verify current placement through the Humana online formulary lookup tool or by calling the member services number on the back of their insurance card. Formulary tier placement can shift at the start of each plan year, so a drug that was Tier 2 in January could move to Tier 3 in the following cycle.

For Humana Medicare Advantage (MA) enrollees, coverage depends on the specific Part D plan attached to their MA benefit. The Centers for Medicare & Medicaid Services (CMS) requires Part D plans to cover at least two drugs per therapeutic class, and injectable testosterone typically meets this requirement. However, MA plans have more latitude to impose quantity limits and require prior authorization than standard commercial plans do [1].

Generic testosterone cypionate 200 mg/mL is the most commonly covered formulation. A typical prescription of 1 mL every two weeks gives patients a monthly cost that falls well below the $100 list price of the branded version. Patients filling at Humana's preferred mail-order pharmacy (CenterWell Pharmacy, formerly Humana Pharmacy) may see even lower out-of-pocket costs.

Prior Authorization Requirements on Humana

Humana requires prior authorization for testosterone cypionate on a moderate percentage of its plans, and the requirement is near-universal on Medicare Advantage products. The PA process exists to confirm that the prescription aligns with FDA-approved indications for male hypogonadism rather than off-label uses such as age-related testosterone decline without clinical symptoms.

To satisfy Humana's PA criteria, prescribers typically must submit:

• Two morning serum total testosterone levels below 300 ng/dL, drawn between 6:00 AM and 10:00 AM on separate days, consistent with the Endocrine Society Clinical Practice Guideline (2018) recommendation for diagnosis of hypogonadism [2].
• Documentation of signs or symptoms of testosterone deficiency (fatigue, decreased libido, erectile dysfunction, loss of muscle mass, depressed mood).
• An ICD-10 diagnosis code for hypogonadism (E29.1 for testicular hypofunction, E89.5 for post-procedural testicular hypofunction, or related codes).
• Confirmation that the patient does not have contraindications, including breast or prostate cancer, polycythemia with hematocrit above 54%, untreated severe sleep apnea, or uncontrolled heart failure.

The Endocrine Society guideline specifically recommends against prescribing testosterone to men who are planning fertility in the near term, as exogenous testosterone suppresses spermatogenesis [2]. Humana reviewers may flag PA requests that lack fertility counseling documentation for men of reproductive age.

Turnaround time for a standard PA request is 5 to 7 business days on commercial plans. Urgent requests can be processed in 24 to 72 hours. If the initial PA is denied, the explanation of benefits letter will include the specific clinical rationale and instructions for appeal.

Step Therapy Policies

Most Humana commercial plans do not impose formal step therapy for testosterone cypionate injections. The drug is already one of the lowest-cost testosterone replacement options, so requiring a trial of an even cheaper alternative is uncommon.

Some Humana Medicare Advantage plans, however, do include a step-therapy edit that requires documentation of a trial (or clinical contraindication to) topical testosterone gel before approving injectable cypionate. This reflects a CMS-permitted formulary management tool, not a blanket Humana policy.

If your Humana MA plan requires step therapy, the prescriber can request an exception by documenting:

• Prior use of topical testosterone with inadequate response (serum testosterone remaining below 400 ng/dL after 90 days of compliant use).
• Skin conditions, transfer risk concerns (household contact with women or children), or adherence barriers that make topical formulations clinically inappropriate.
• Patient preference alone typically does not satisfy step-therapy exception criteria.

The T-Trials, a coordinated set of seven placebo-controlled studies enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, showed that testosterone treatment improved sexual function, physical function, and mood over 12 months [3]. These findings apply regardless of testosterone delivery method, which gives prescribers clinical grounds to argue that injectable and topical routes are therapeutically equivalent and that step therapy from one to the other adds cost without clinical benefit.

How to Appeal a Humana Denial

A denied prior authorization is not the end of the road. Humana's appeals process follows a structured sequence, and success rates for testosterone cypionate appeals are reasonable when supported by proper documentation.

Step 1: Internal appeal. The member or prescriber has 180 days (commercial) or 60 days (MA) from the date of the denial letter to file an internal appeal. Include updated lab results, a letter of medical necessity from the prescribing physician, and any relevant guideline citations. The American Urological Association (AUA) guideline on testosterone deficiency (2018) is a strong supporting reference, as it recommends testosterone therapy for men with consistently low serum testosterone and associated symptoms [4].

Step 2: External review. If the internal appeal is denied on a commercial plan, Humana must offer an independent external review conducted by a third-party organization. The external reviewer examines the clinical evidence without deference to Humana's initial decision.

Step 3: Medicare-specific pathway. For MA plan denials, after the internal appeal (called a "reconsideration"), the next level is an Independent Review Entity (IRE) review, currently administered by MAXIMUS Federal Services. MAXIMUS reviews are free to the member and must be completed within 7 calendar days for standard requests. Beyond MAXIMUS, members can escalate to an Administrative Law Judge hearing if the amount in controversy exceeds $180 (2026 threshold) [5].

Practical tips for a stronger appeal:

• Reference specific guideline language. Quote the Endocrine Society's recommendation that "testosterone therapy is recommended for men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, and bone mineral density" [2].
• Include before-and-after labs if the patient previously responded to testosterone cypionate and is being denied a continuation.
• Document functional impairment. Describe how symptoms affect work, relationships, and quality of life.
• Request a peer-to-peer review between the prescriber and Humana's medical director. These conversations resolve a meaningful share of denials without a formal appeal.

Cost Comparison: Humana vs. Cash Pay

The arithmetic of coverage versus cash pay matters for testosterone cypionate because the drug is inexpensive even without insurance. Generic testosterone cypionate 200 mg/mL (10 mL vial) averages $40 to $80 at retail pharmacies using a GoodRx or similar discount card. Branded Depo-Testosterone runs closer to $100.

For Humana members with a $30 copay on a Tier 3 drug, insurance saves roughly $10 to $50 per month compared to cash pay. But if prior authorization is denied and the appeal process takes weeks, the immediate cost of paying cash may be lower than the indirect costs of treatment interruption.

A 2020 analysis published in the Journal of the Endocrine Society found that treatment interruptions in testosterone replacement therapy were associated with return of hypogonadal symptoms within 3 to 4 weeks and measurable declines in bone mineral density markers after 6 months of discontinuation [6]. The clinical cost of a coverage gap, in other words, extends beyond the pharmacy receipt.

Humana members who use CenterWell Pharmacy (Humana's integrated mail-order service) may access 90-day supply pricing that brings the per-month cost below $15 on some plans. This option is worth exploring before abandoning insurance coverage in favor of cash pay.

Testosterone Cypionate and Weight Loss: What Humana Will Not Cover

Humana does not cover testosterone cypionate for weight loss as a primary indication. This policy aligns with FDA labeling, which approves testosterone cypionate only for replacement therapy in males with conditions associated with deficiency or absence of endogenous testosterone [7].

CMS rules further prohibit Medicare Part D plans from covering drugs prescribed for weight loss, cosmetic purposes, or sexual dysfunction as the sole diagnosis. If a prescriber submits a PA for testosterone cypionate with an ICD-10 code for obesity (E66.x) rather than hypogonadism (E29.1), Humana will deny the claim automatically.

There is clinical nuance here. Testosterone replacement in hypogonadal men does produce favorable body composition changes. The Testosterone Trials showed a mean increase in lean body mass of 0.6 kg and a decrease in fat mass of 0.5 kg over 12 months compared to placebo [3]. A meta-analysis of 37 randomized controlled trials (N = 3,053) published in Clinical Endocrinology found that testosterone therapy reduced fat mass by an average of 1.6 kg (95% CI: -2.0 to -1.2 kg) [8]. These changes are real but are classified as secondary benefits of treating hypogonadism, not standalone weight-loss outcomes.

For Humana members seeking testosterone cypionate, the prescription must be anchored to a hypogonadism diagnosis with supporting lab work. Any body composition improvements are a clinical bonus, not a reimbursable indication.

Manufacturer Savings Cards and Humana

Manufacturer copay assistance cards for branded Depo-Testosterone (Pfizer) can reduce out-of-pocket costs to as low as $0 for commercially insured patients. These cards are accepted at most retail pharmacies and can be applied at the point of sale alongside Humana commercial insurance.

There are two important restrictions:

1. Medicare Advantage members cannot use manufacturer copay cards. The federal Anti-Kickback Statute prohibits pharmaceutical manufacturers from subsidizing copays for Medicare beneficiaries. Humana MA members who attempt to use a copay card will have it rejected at the pharmacy.

2. Copay accumulator programs. Some Humana commercial plans use copay accumulator adjusters, which means manufacturer copay card payments do not count toward the member's annual deductible or out-of-pocket maximum. Under these plans, the copay card provides short-term relief but does not accelerate the path to catastrophic coverage.

For patients on generic testosterone cypionate (which accounts for the vast majority of prescriptions), manufacturer cards are irrelevant. The generic price is low enough that standard insurance copays are typically manageable. Patients paying $10 to $30 per month through Humana are unlikely to find a copay card that offers meaningful additional savings on a generic product.

Monitoring Requirements That Affect Ongoing Coverage

Humana may require periodic re-authorization for testosterone cypionate, particularly on MA plans. Re-authorization intervals vary by plan but commonly occur every 6 to 12 months. To maintain continuous coverage, patients and prescribers should keep monitoring labs current.

The Endocrine Society recommends the following monitoring schedule for men on testosterone replacement therapy [2]:

• Serum testosterone level at 3 months, then every 6 to 12 months. Target trough level: 400 to 700 ng/dL.
• Hematocrit at 3 months, then every 6 to 12 months. If hematocrit exceeds 54%, the dose should be reduced, or therapy paused, and the patient evaluated for sleep apnea or other causes of polycythemia.
• PSA (prostate-specific antigen) at 3 to 6 months, then per standard screening guidelines. A PSA increase greater than 1.4 ng/mL within 12 months of starting therapy warrants urological referral [9].
• Lipid panel and hepatic function at baseline and periodically during therapy.
• Bone mineral density after 1 to 2 years in men with osteoporosis or at baseline if the patient has risk factors.

Failure to document these monitoring labs is a common reason for re-authorization denial. Prescribers should proactively order labs 2 to 4 weeks before the re-authorization date and upload results to Humana's PA portal.

A study in The Journal of Clinical Endocrinology & Metabolism followed 1,031 hypogonadal men on testosterone therapy and found that adherence to monitoring guidelines was associated with a 23% reduction in adverse cardiovascular events compared to men who received testosterone without structured follow-up [10]. Regular monitoring is not just an insurance requirement. It is a patient safety measure that guidelines support with strong evidence.